The Healthy Aging study focuses on advancing brain health and preventing age-related diseases like Alzheimer’s and investigates a wide range of shared risk factors for other conditions such as heart disease, diabetes and hypertension.
The Healthy Brain Study focuses on developing biomarkers that enable prediction of Alzheimer’s disease in middle-age individuals, even before symptoms begin.
Identifying individuals at risk for Alzheimer’s disease created an imperative for the Emory ADRC team to expand testing and conduct clinical trials that would offer hope to these individuals. “This new gift from The Goizueta Foundation will allow us to eventually offer therapies to affected individuals with the key goals to either delay development of Alzheimer’s or halt it altogether,” says Dr. Allan Levey, the center’s director.
Based on recent research discoveries, Emory investigators expect to soon have several promising biomarker candidates that can pinpoint the development of Alzheimer’s disease symptoms a decade or more before the onset of cognitive decline and memory loss, not only allowing for earlier detection but also making it possible to create fundamental changes in the treatment of this debilitating disease.
The Goizueta Alzheimer’s Disease Research Center is part of the Emory Brain Health Center and is one of 32 Alzheimer’s disease research centers nationally, and one of only a few in the Southeast, that are supported by the National Institutes of Health. This network of Alzheimer’s disease research centers is working collaboratively to find a treatment for the disease by 2025.